Debate: Statins should be used in patients with heart failureIncreased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failureStatins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsClinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-conveComparison of baseline data, initial course, and management: losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the ATelomere length and outcomes in ischaemic heart failure: data from the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA).Omega-3 fatty acids improve blood pressure control and preserve renal function in hypertensive heart transplant recipients.Exercise capacity in heart transplant recipients: relation to impaired endothelium-dependent vasodilation of the peripheral microcirculation.Effect of metoprolol on cytokine levels in chronic heart failure--a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF).Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial.Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering.Effect of enalapril on mortality in congestive heart failure. Follow-up survival data from the CONSENSUS trial.The magnesium loading test: reference values in healthy subjects.Effects of ACE2 inhibition in the post-myocardial infarction heart.Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).The homeostatic chemokine CCL21 predicts mortality and may play a pathogenic role in heart failure.ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collabLipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)CCL21 is associated with fatal outcomes in chronic heart failure: data from CORONA and GISSI-HF trials.Rosuvastatin in older patients with systolic heart failure.Influence of heart rate on mortality after acute myocardial infarction.Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial inHMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA).Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).Inflammation: Friend and FoeAgents targeting inflammation in heart failure.Overdrive suppression of implanted pacemakers in patients with AV block.Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptideValvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study.An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial.Diabetic patients and beta-blockers after acute myocardial infarction.The Seattle Post Myocardial Infarction Model (SPIM): prediction of mortality after acute myocardial infarction with left ventricular dysfunction.High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction.Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study.Arrhythmias and mortality in congestive heart failure.
P50
Q24799320-FA04A3BC-2F5D-4287-BBB4-AC92CE3F0987Q28575465-3C427C85-9F81-4774-9C7F-3742F61DB9C3Q29622947-0DCF40EC-2FAB-4354-9BE7-FA703769C677Q30597068-5AE90AF2-2439-42DA-9EF3-12D05F2B9D95Q30638921-D9C72BEB-9B34-4F1D-8F5C-656F1FA67E39Q30886908-932A63C7-7C5A-4D56-B26D-DFDD4FDB6350Q32023336-033E1606-D522-4281-9DC3-DE8E08172CA2Q32038973-BD2AD357-6930-42EF-A04D-3A977DABBB6FQ32083263-6DB62861-B03C-487A-9CC0-7411D7891EC6Q33433326-8D230D27-25C0-4C0B-B743-8A8FCE512935Q33893139-0405BAD0-856C-4FEB-AFCF-46F493E57F23Q33912099-A50774C4-142C-4EF4-BD60-0E70D99BF8D5Q34019737-447EC9AF-FCA3-4CD9-B59A-7B1C6E4D43FBQ34060681-027F8AD4-7BC5-4E45-A234-2176AA5E533EQ34088930-0109398F-9FD6-46E3-A267-3883B4A729F1Q34150300-FF485A2D-21F8-48BE-82C5-71DF78964140Q34196167-5EA7DB95-6161-4FF9-84E3-B52C64CA5BAAQ34200352-5FF9AD4C-FF26-4DB6-B88E-4CAF037C9CA0Q34212424-07E368A8-B260-4CDD-8919-664F0023705DQ34269132-D3B90470-3FF6-4686-8EC7-EB790AB647E7Q34368081-F819C6FE-A550-4988-9B42-E9405B89A0D9Q34467101-40F666D8-AE2A-43BA-A6E3-51AF1D30ADEBQ34619812-2DE9A2A3-DFB2-4725-B45C-023C9DC8E554Q34710349-21F0991B-5069-4A8C-98BD-69460AF02A0CQ34997898-2FBB5EFE-68BD-4B37-8EA5-809B183E83F6Q35011439-C023E912-907E-4FB5-95D2-BCFF281E9BF4Q35065253-2954B6EA-A13C-428F-96B2-F79A60DED0E5Q35531512-D1E5E08F-0128-44A5-962F-5992E987F3AEQ35750462-757BA71C-171A-485F-B96F-1F4029DBE4EEQ35947550-A2A412B2-B112-4323-9286-05E624FCEF75Q36145827-9A7EF62C-3D1D-46C2-BF0B-11A242746D8BQ36787630-9856D323-466F-44AD-8BD0-DC3A28862255Q37102996-6D52C2D0-F0D7-461F-98EA-E928E9D96949Q37330650-6F4FB705-DEB8-42E9-BF14-6079C79E842DQ37484543-242E0E4E-DB1F-4E3E-AED9-F2E185BA6B60Q37580540-B8329199-ACE2-4886-B8AB-030276A796DBQ37599588-45BF977A-ECE1-4923-A2F3-073AC07F888BQ37665053-8EA62295-0A0A-4E01-B5EB-FC51CDE51E14Q37871076-4140F332-88CF-450C-99CD-5000D283FF10Q37877446-46414896-8108-4254-B14E-8A1B570B0FA3
P50
subject
description
Noors cardioloog
@nl
Norwegian cardiologist
@en
cardiólogu noruegu
@ast
norwegischer Kardiologe
@de
طبيب قلب نرويجي
@ar
name
John Kjekshus
@ast
John Kjekshus
@ca
John Kjekshus
@de
John Kjekshus
@en
John Kjekshus
@es
John Kjekshus
@fr
John Kjekshus
@ga
John Kjekshus
@nl
John Kjekshus
@sl
John Kjekshus
@sq
type
label
John Kjekshus
@ast
John Kjekshus
@ca
John Kjekshus
@de
John Kjekshus
@en
John Kjekshus
@es
John Kjekshus
@fr
John Kjekshus
@ga
John Kjekshus
@nl
John Kjekshus
@sl
John Kjekshus
@sq
prefLabel
John Kjekshus
@ast
John Kjekshus
@ca
John Kjekshus
@de
John Kjekshus
@en
John Kjekshus
@es
John Kjekshus
@fr
John Kjekshus
@ga
John Kjekshus
@nl
John Kjekshus
@sl
John Kjekshus
@sq
P1006
P1015
P214
P1006
P1015
P106
P21
P214
P27
P31
P569
1936-03-11T00:00:00Z
P734
P735
P7859
viaf-306158926